| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
CTNM
Contineum Therapeutics, Inc. Class A
|
Aug 14, 2026 | BUY |
Strong Buy
+52.0% avg upside
9 analysts
|
$28.00
97.38% Upside
|
+0.0% | · |
|
SPTX
Seaport Therapeutics, Inc.
|
Aug 13, 2026 | BUY |
Strong Buy
+58.6% avg upside
6 analysts
|
$30.00
23.91% Upside
|
+2.1% | · |
|
LBRX
LB Pharmaceuticals, Inc.
|
Aug 13, 2026 | BUY |
Strong Buy
+0.9% avg upside
8 analysts
|
$53.00
10.97% Upside
|
+7.9% | · |
|
RAPP
Rapport Therapeutics, Inc.
|
Aug 13, 2026 | BUY |
Strong Buy
+21.8% avg upside
14 analysts
|
$56.00
18.01% Upside
|
+0.1% | · |
|
PEPG
PepGen Inc.
|
Aug 13, 2026 | BUY |
Strong Buy
+256.0% avg upside
9 analysts
|
$12.00
301.25% Upside
|
+0.3% | · |
|
CMPS
COMPASS Pathways
|
Aug 13, 2026 | BUY |
Strong Buy
+65.6% avg upside
20 analysts
|
$21.00
56.04% Upside
|
+1.2% | · |
|
XENE
Xenon
|
Aug 13, 2026 | BUY |
Strong Buy
-0.4% avg upside
28 analysts
|
$86.00
37.93% Upside
|
-2.9% | · |
|
QURE
uniQure
|
Aug 13, 2026 | BUY |
Strong Buy
+22.9% avg upside
29 analysts
|
$71.00
46.06% Upside
|
+3.3% | · |
|
NGNE
Neurogene
|
Aug 13, 2026 | BUY |
Strong Buy
+35.4% avg upside
23 analysts
|
$46.00
27.37% Upside
|
+1.4% | · |
|
ALNY
Alnylam Pharma
|
Aug 13, 2026 | BUY |
Strong Buy
+41.8% avg upside
51 analysts
|
$318.00
39.02% Upside
|
+0.7% | · |
|
BMRN
BioMarin Pharmaceutical
|
Aug 11, 2026 | HOLD |
Strong Buy
+40.3% avg upside
52 analysts
|
$70.00
3.99% Upside
|
-3.1% | · |
|
SION
Sionna Therapeutics, Inc.
|
Aug 10, 2026 | HOLD |
Hold
+232.2% avg upside
12 analysts
|
$7.00
8.36% Upside
|
+43.6% | · |
|
VRTX
Vertex Pharmaceuticals
|
Aug 09, 2026 | HOLD |
Strong Buy
-12.3% avg upside
62 analysts
|
$500.00
1.20% Downside
|
+0.4% | · |
|
DNLI
Denali Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+57.2% avg upside
24 analysts
|
$41.00
68.11% Upside
|
-1.7% | · |
|
DFTX
Definium Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+18.0% avg upside
21 analysts
|
$60.00
40.74% Upside
|
-7.6% | · |
|
GHRS
GH Research
|
Aug 06, 2026 | BUY |
Strong Buy
+34.4% avg upside
12 analysts
|
$38.00
28.82% Upside
|
-3.8% | · |
|
ACAD
ACADIA Pharmaceuticals
|
Aug 05, 2026 | HOLD |
Strong Buy
+29.5% avg upside
43 analysts
|
$25.00
11.51% Downside
|
-1.9% | · |
|
IONS
Ionis Pharmaceuticals
|
Aug 02, 2026 | HOLD |
Strong Buy
+39.1% avg upside
43 analysts
|
$68.00
18.73% Upside
|
+4.5% | · |
|
BIIB
Biogen
|
Aug 02, 2026 | BUY |
Strong Buy
+21.0% avg upside
52 analysts
|
$242.00
15.36% Upside
|
+4.0% | · |
|
DYN
Dyne Therapeutics
|
Jul 31, 2026 | BUY |
Strong Buy
+55.0% avg upside
31 analysts
|
$37.00
44.01% Upside
|
+2.1% | · |
|
NBIX
Neurocrine
|
Jul 31, 2026 | BUY |
Strong Buy
+22.8% avg upside
37 analysts
|
$215.00
40.74% Upside
|
-6.2% | · |
|
ALKS
Alkermes
|
Jul 25, 2026 | BUY |
Strong Buy
-15.5% avg upside
34 analysts
|
$63.00
28.36% Upside
|
-6.2% | · |
|
LXEO
Lexeo Therapeutics, Inc.
|
Jul 06, 2026 | BUY |
Strong Buy
+298.4% avg upside
11 analysts
|
$17.00
251.22% Upside
|
+5.2% | · |
|
VTGN
VistaGen Therapeutics
|
Jul 06, 2026 | HOLD |
Hold
+875.1% avg upside
8 analysts
|
$1.00
273.62% Upside
|
+8.0% | · |
|
RYTM
Rhythm Pharmaceuticals
|
Jun 15, 2026 | BUY |
Strong Buy
+8.0% avg upside
20 analysts
|
$133.00
15.14% Upside
|
+28.7% | · |
|
MPLT
MapLight Therapeutics, Inc.
|
Jun 02, 2026 | BUY |
Strong Buy
+153.2% avg upside
13 analysts
|
$36.00
206.33% Upside
|
-57.0% | · |
|
IMUX
Immunic
|
May 28, 2026 | BUY |
Strong Buy
+136.7% avg upside
21 analysts
|
$25.00
55.63% Upside
|
+7.3% | · |
|
NMRA
Neumora Therapeutics, Inc.
|
May 12, 2026 | HOLD |
Buy
+367.6% avg upside
11 analysts
|
$3.00
87.52% Upside
|
-15.8% | · |
|
ANRO
Alto Neuroscience, Inc.
|
Apr 02, 2026 | BUY |
Strong Buy
-2.3% avg upside
13 analysts
|
$33.00
2.61% Upside
|
+48.2% | · |
|
ALEC
Alector
|
Dec 22, 2025 | HOLD |
Buy
+393.9% avg upside
14 analysts
|
— | +35.2% | · |
|
ABOS
Acumen Pharmaceuticals
|
Dec 16, 2025 | BUY |
Strong Buy
+211.0% avg upside
10 analysts
|
$10.00
274.58% Upside
|
+27.1% | · |
|
LONA
LeonaBio
|
Sep 19, 2024 | HOLD |
Buy
+38.8% avg upside
9 analysts
|
— | -16.8% | · |
|
CLYM
Climb Bio
|
Jun 03, 2023 | BUY |
Strong Buy
+18.9% avg upside
19 analysts
|
$5.00
69.35% Downside
|
+182.7% | · |
|
WVE
Wave Life Sciences
|
May 12, 2022 | HOLD |
Strong Buy
+295.7% avg upside
28 analysts
|
$3.00
44.59% Downside
|
+207.8% | · |
|
IRON
Disc Medicine
|
Feb 28, 2022 | HOLD |
Strong Buy
+10.4% avg upside
21 analysts
|
$20.00
74.65% Downside
|
-38.7% | · |
|
OBSEF
ObsEva
|
Aug 16, 2017 | BUY |
Buy
+1079999900.0% avg upside
8 analysts
|
$18.00
1799999899.99% Upside
|
· | · |
|
NBRVF
Nabriva Therapeutics
|
Mar 10, 2017 | BUY |
Buy
+13374900.0% avg upside
9 analysts
|
$20.00
19999899.93% Upside
|
· | · |
|
ACIU
AC Immune SA
|
Nov 23, 2016 | BUY |
Strong Buy
+218.0% avg upside
5 analysts
|
— | -1.4% | · |
|
TBPH
Theravance Biopharma
|
Jun 20, 2016 | BUY |
Buy
+8.7% avg upside
18 analysts
|
$29.00
70.82% Upside
|
+70.2% | · |
|
FATE
Fate Therapeutics
|
Jun 20, 2016 | BUY |
Buy
+372.0% avg upside
31 analysts
|
— | +49.0% | · |
|
TPST
Tempest Therapeutics
|
May 06, 2016 | HOLD |
Buy
+2038.6% avg upside
18 analysts
|
$7.00
589.57% Upside
|
· | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.